News & Events
2026/05/22
Bringing Hope to Those Awaiting Sight: Red Cross and ACROBiomedical Advance Corneal Care Philanthropy
Pan Wei-Ta, President of the Red Cross (left), and Dr. Dar-Jen Hsieh, Chairman of ACROBiomedical (right), jointly sign a MOU, pledging to leverage a philanthropic network to bridge the healthcare divide.
When cutting-edge medical technology intersects with compassionate humanitarian action, vulnerable patients awaiting critical treatment gain a renewed pathway to hope. On May 21, the Red Cross Society of the Republic of China (Taiwan) forged a strategic philanthropic partnership with ACROBiomedical Co., Ltd. This collaboration seamlessly integrates ACROBiomedical's pioneering collagen biomaterial technology with the extensive humanitarian network of the Red Cross, aiming to provide comprehensive support for underprivileged patients, military personnel, and their families throughout their journeys of vision restoration, wound management, and post-surgical recovery.
For individuals suffering from corneal damage due to trauma, infection, ulcers, or disease, deteriorating vision presents far more than a clinical challenge—it often carries the profound fear of blindness, immense caregiving strain, and the severe economic hardship of lost income. According to statistics from the Taiwan Organ Registry and Sharing Center, more than 1,500 patients across the nation are currently on the waiting list for corneal transplants. However, as of late April this year (2026), only 155 successful donations have been recorded, underscoring a critical and persistent disparity between supply and demand.
In recent years, ophthalmic medicine has progressively evolved toward a philosophy of "restoration rather than replacement." By leveraging regenerative medicine materials to repair damaged tissue and stimulate cellular regeneration, clinicians can now offer patients more immediate and flexible treatment options beyond traditional corneal transplantation. Nevertheless, the substantial costs associated with these advanced therapies often remain an insurmountable financial burden for economically disadvantaged families.
Through this landmark initiative, ACROBiomedical will donate two of its innovative medical devices: the Collagen Corneal Matrix and the Collagen Hemostatic Dressing. Pan Wei-Ta, President of the Red Cross, emphasized that the core mission of humanitarian work is to alleviate human suffering to the greatest extent possible, noting that countless vulnerable groups across society continue to face severe shortages of medical resources. Invoking the classical ideal of "the ultimate chivalry lies in serving the nation and its people," President Pan commended ACROBiomedical and the broader medical community for their long-standing dedication to public welfare. He expressed confidence that this partnership will effectively address the gaps in corneal treatment resources, ensuring that the fruits of medical technology and the spirit of universal humanitarian love reach remote communities and every corner where support is most urgently needed.
Reflecting on his enduring connection with the organization, Dr. Dar-Jen Hsieh, Chairman of ACROBiomedical, shared that he had served as a postdoctoral researcher at the American Red Cross Jerome H. Holland Laboratory three decades ago, forging a deep and lasting bond with the Red Cross movement. ACROBiomedical has long been steadfast in its commitment to medical philanthropy, having previously donated advanced medical dressings to aid victims of the Kaohsiung gas explosions and injured armed forces personnel in Pingtung. Chairman Hsieh noted that corporate investment in regenerative medicine and biomaterial research extends beyond technological innovation; its ultimate purpose is to address real societal needs. This partnership with the Red Cross represents a concerted effort to leverage philanthropic synergy to bridge the healthcare divide, enabling more patients to receive timely treatment and high-quality care.
The Red Cross strictly underscores that this collaboration is rooted entirely in philanthropy and humanitarian concern, devoid of any commercial promotion or product endorsement. Moving forward, the Society will establish collaborative workflows with participating medical institutions under the principles of compliance, transparency, and utmost respect for medical expertise, ensuring that this benevolent initiative directly benefits those in genuine need.
For individuals suffering from corneal damage due to trauma, infection, ulcers, or disease, deteriorating vision presents far more than a clinical challenge—it often carries the profound fear of blindness, immense caregiving strain, and the severe economic hardship of lost income. According to statistics from the Taiwan Organ Registry and Sharing Center, more than 1,500 patients across the nation are currently on the waiting list for corneal transplants. However, as of late April this year (2026), only 155 successful donations have been recorded, underscoring a critical and persistent disparity between supply and demand.
In recent years, ophthalmic medicine has progressively evolved toward a philosophy of "restoration rather than replacement." By leveraging regenerative medicine materials to repair damaged tissue and stimulate cellular regeneration, clinicians can now offer patients more immediate and flexible treatment options beyond traditional corneal transplantation. Nevertheless, the substantial costs associated with these advanced therapies often remain an insurmountable financial burden for economically disadvantaged families.
Through this landmark initiative, ACROBiomedical will donate two of its innovative medical devices: the Collagen Corneal Matrix and the Collagen Hemostatic Dressing. Pan Wei-Ta, President of the Red Cross, emphasized that the core mission of humanitarian work is to alleviate human suffering to the greatest extent possible, noting that countless vulnerable groups across society continue to face severe shortages of medical resources. Invoking the classical ideal of "the ultimate chivalry lies in serving the nation and its people," President Pan commended ACROBiomedical and the broader medical community for their long-standing dedication to public welfare. He expressed confidence that this partnership will effectively address the gaps in corneal treatment resources, ensuring that the fruits of medical technology and the spirit of universal humanitarian love reach remote communities and every corner where support is most urgently needed.
Reflecting on his enduring connection with the organization, Dr. Dar-Jen Hsieh, Chairman of ACROBiomedical, shared that he had served as a postdoctoral researcher at the American Red Cross Jerome H. Holland Laboratory three decades ago, forging a deep and lasting bond with the Red Cross movement. ACROBiomedical has long been steadfast in its commitment to medical philanthropy, having previously donated advanced medical dressings to aid victims of the Kaohsiung gas explosions and injured armed forces personnel in Pingtung. Chairman Hsieh noted that corporate investment in regenerative medicine and biomaterial research extends beyond technological innovation; its ultimate purpose is to address real societal needs. This partnership with the Red Cross represents a concerted effort to leverage philanthropic synergy to bridge the healthcare divide, enabling more patients to receive timely treatment and high-quality care.
The Red Cross strictly underscores that this collaboration is rooted entirely in philanthropy and humanitarian concern, devoid of any commercial promotion or product endorsement. Moving forward, the Society will establish collaborative workflows with participating medical institutions under the principles of compliance, transparency, and utmost respect for medical expertise, ensuring that this benevolent initiative directly benefits those in genuine need.
Pan Wei-Ta, President of the Red Cross (center), alongside Vice President Tsao Erh-chung (right), tours the ACROBiomedical facility to gain insight into the production processes of regenerative medicine materials and related products.
Witnessed by distinguished guests, the Red Cross and ACROBiomedical forge a strategic philanthropic partnership to jointly provide critical medical support and care resources for underprivileged patients, military personnel, and their families.